Pharmacoepidemiology and Drug Safety, 1053-8569

Journal

More filtering options
  1. 2021
  2. Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma

    Lasse Hjort Jakobsen, Torbjörn Callréus, Maurizio Sessa, Mats Jerkeman, Morten Andersen & Tarec Christoffer El-Galaly, 2021, In: Pharmacoepidemiology and Drug Safety.

    Research output: Contribution to journalArticle

  3. 2016
  4. Testosterone prescribing in the population-a short social epidemiological analysis in Sweden.

    Pernilla Bjerkeli, Shai Mulinari & Juan Merlo, 2016, In: Pharmacoepidemiology and Drug Safety. 25, 1, p. 11-15

    Research output: Contribution to journalArticle

  5. 2014
  6. Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study

    Gunilla Ringback Weitoft, Mats Berglund, Eva A. Lindstrom, Mikael Nilsson, Peter Salmi & Mans Rosen, 2014, In: Pharmacoepidemiology and Drug Safety. 23, 3, p. 290-298

    Research output: Contribution to journalArticle

  7. 2011
  8. Re: How can we produce relevant information for decision makers from small area variation studies?

    Henrik Ohlsson & Juan Merlo, 2011, In: Pharmacoepidemiology and Drug Safety. 20, 7, p. 780-781

    Research output: Contribution to journalLetter

  9. Statin Prescribing in Patients with Newly Diagnosed Type 2 Diabetes Mellitus +/- a Multilevel Analysis

    Henrik Ohlsson, Mark Nielen & Liset Van Dijk, 2011, In: Pharmacoepidemiology and Drug Safety. 20, p. 673

    Research output: Contribution to journalPublished meeting abstract

  10. 2010
  11. Increased risk of abdominal wall hernia associated with combination anti-retroviral therapy in HIV-infected patients-results from a Swedish cohort-study

    Anders Sundstrom, Orjan Mortimer, Borje Akerlund, Anders Karlsson, Leo Flamholc, Camilla Hakangard, Helena Granholm, Ingemar Persson & Linda Morfeldt, 2010, In: Pharmacoepidemiology and Drug Safety. 19, 5, p. 465-473

    Research output: Contribution to journalArticle

  12. Socioeconomic position and secondary preventive therapy after an AMI.

    Henrik Ohlsson, Maria Rosvall, Ole Hansen, Basile Chaix & Juan Merlo, 2010, In: Pharmacoepidemiology and Drug Safety. 19, p. 358-366

    Research output: Contribution to journalArticle

  13. 2009
  14. Adherence to diagnostic guidelines and quality indicators in asthma and COPD in Swedish primary care.

    Paolina Weidinger, J Lars G Nilsson & Ulf Lindblad, 2009, In: Pharmacoepidemiology and Drug Safety. 18, p. 393-400

    Research output: Contribution to journalArticle

  15. 2008
  16. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.

    Cecilia Aström-Lilja, Johanna Mercke Odeberg, Elisabet Ekman & Staffan Hägg, 2008, In: Pharmacoepidemiology and Drug Safety. 17, 6, p. 587-592

    Research output: Contribution to journalArticle

  17. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn.

    Bengt Källén & Petra Otterblad Olausson, 2008, In: Pharmacoepidemiology and Drug Safety. 17, p. 801-806

    Research output: Contribution to journalArticle

  18. Quality assessment indicators at diagnosis and at follow-up of patients with asthma and COPD: The skaraborg primary care research database

    Paolina Weidinger, J. Lars G. Nilsson & Ulf Lindblad, 2008, In: Pharmacoepidemiology and Drug Safety. 17, s1, p. S100-S101

    Research output: Contribution to journalPublished meeting abstract

  19. 2007
  20. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics

    Birgitta Norstedt Wikner, Carl-Olav Stiller, Bengt Källén & Charlotte Asker, 2007, In: Pharmacoepidemiology and Drug Safety. 16, 9, p. 988-994

    Research output: Contribution to journalArticle

  21. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations

    Birgitta Norstedt Wikner, Carl-Olav Stiller, Ulf Bergman, Charlotte Asker & Bengt Källén, 2007, In: Pharmacoepidemiology and Drug Safety. 16, 11, p. 1203-1210

    Research output: Contribution to journalArticle

  22. 2006
  23. No association between inhaled corticosteroids and whole body DXA in postmenopausal women.

    Sölve Elmståhl, Henrik Ekström, Olof Johnell, Maria Gerhardsson de Verdier & Ensio Norjavaara, 2006, In: Pharmacoepidemiology and Drug Safety. 15, May 22, p. 527-535

    Research output: Contribution to journalArticle

  24. 2004
  25. Re: accuracy of pharmacy records

    Anders Ekedahl, 2004, In: Pharmacoepidemiology and Drug Safety. 13, 12, p. 877-877

    Research output: Contribution to journalLetter

  26. Use of inhaled corticosteroids and bone mineral density in a population based study: the Nord-Trondelag Health Study (the HUNT Study)

    A Langhaminer, E Norjavaara, MG de Verdier, R Johnsen & Leif Bjermer, 2004, In: Pharmacoepidemiology and Drug Safety. 13, 8, p. 569-579

    Research output: Contribution to journalArticle

  27. 2002
  28. Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project.

    Erik Bøg-Hansen, Ulf Lindblad, Jonas Ranstam, Arne Melander & Lennart Råstam, 2002, In: Pharmacoepidemiology and Drug Safety. 11, 1, p. 45-54

    Research output: Contribution to journalArticle

  29. Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study

    Gunnar Lindberg, Ulf Lindblad, Bent Löw-Larsen, Juan Merlo, Arne Melander & Lennart Råstam, 2002, In: Pharmacoepidemiology and Drug Safety. 11, 6, p. 493-497

    Research output: Contribution to journalArticle

  30. 2001
  31. Antidepressant medication and suicide in Sweden

    A Carlsten, M Waern, Anders Ekedahl & J Ranstam, 2001, In: Pharmacoepidemiology and Drug Safety. 10, 6, p. 525-530

    Research output: Contribution to journalArticle

  32. 2000